Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 26, 2007. The report serves as a notification of transactions involving Directors or Persons Discharging Managerial Responsibility, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction by Dr. R G Greig:
- Option Exercise: On February 23, 2007, Dr. Greig exercised options over 45,000 ADSs granted on December 15, 2003, at a price of $44.57 per ADS.
- Share Sale: On the same date, 45,000 ADSs were sold at a price of $56.81 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the aforementioned transaction.
Investor Verification Points
- Verify the total number of ADSs held by Dr. R G Greig following the February 23, 2007 transaction.
- Confirm the terms of the GlaxoSmithKline Share Option Plan under which the options were granted in December 2003.
- Review the company's broader financial reports (e.g., Form 20-F) for comprehensive financial metrics not included in this 6-K.